-
公开(公告)号:US20070172430A1
公开(公告)日:2007-07-26
申请号:US11623306
申请日:2007-01-15
申请人: Luis Brito , Donghao Chen , Qing Ge , Doug Treco
发明人: Luis Brito , Donghao Chen , Qing Ge , Doug Treco
CPC分类号: A61K9/0075 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12N2760/16111
摘要: A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus.
摘要翻译: 用于粘膜,鼻内,吸入或肺部递送的干粉制剂,其可以包含一种或多种siRNA或切片剂活性前体,其靶向涉及感染或复制或产生流感病毒的转录物。
-
公开(公告)号:US20110077284A1
公开(公告)日:2011-03-31
申请号:US12903814
申请日:2010-10-13
申请人: Luis Brito , Donghao Chen , Qing Ge , Douglas A. Treco
发明人: Luis Brito , Donghao Chen , Qing Ge , Douglas A. Treco
IPC分类号: A61K31/713 , A61P31/16
CPC分类号: A61K9/0075 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12N2760/16111
摘要: A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of a dry powder formulation.
摘要翻译: 一种用于通过吸入递送至哺乳动物的干粉制剂,该制剂包含包含脂质,载体和靶向流感病毒的一种或多种双链siRNA分子或切片剂活性前体的颗粒。用于治疗或预防流感病毒的方法 哺乳动物包括施用治疗有效量的干粉制剂。
-
公开(公告)号:US06848197B2
公开(公告)日:2005-02-01
申请号:US09837620
申请日:2001-04-18
IPC分类号: A61K9/72 , A61K9/00 , A61K9/14 , A61K9/16 , A61K47/24 , A61L9/04 , B05D7/00 , E02F5/10 , A01N25/02
CPC分类号: A61K9/0075 , A61K9/1694 , Y10S514/951
摘要: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
摘要翻译: 通过雾化液体进料并使液体进料与例如空气或氮气的干燥气体接触来产生具有特定空气动力特性的喷雾干燥颗粒。 干燥气体的湿度被控制为例如表示为露点,其已知产生具有特定振实密度或空气动力学直径的颗粒。 体积中值几何直径大于约5微米且振实密度小于约0.4g / cm 3的颗粒是优选的。
-
4.
公开(公告)号:US5123970A
公开(公告)日:1992-06-23
申请号:US519048
申请日:1990-05-04
申请人: Hongsheng Fang , Yankang Zheng , Xiuyun Chen , Donghao Chen , Rufa Zhao
发明人: Hongsheng Fang , Yankang Zheng , Xiuyun Chen , Donghao Chen , Rufa Zhao
IPC分类号: C22C38/38
CPC分类号: C22C38/38
摘要: Air-hardenable steels of duplex bainite/martensite microstructure consisting essentially of 0.10 to 0.7% C, 0.1 to 2% Si, 2.1 to 3.5% Mn, 0.0005 to 0.005% B, up to 3.5% Cr and preferably containing Cr in amount of at least 0.1%, balance Fe except for incidental impurities. Optional elements are up to 1.5% W, 1.0% Mo, 0.15% V, 0.2% S, 0.1% Ca, 0.1% Pb, 0.1% Ti and 0.2% total rare earths. At least 1.0% Cr is especially preferred and if below such amount, total Mn and Si is at least 3% and in such case, if C is under 0.47%, at least 0.6% Si is present. The steels are hardenable to R.sub.c 2o to R.sub.c 58 and have a hardenable diameter in the range between 35 mm and 80 to 100 mm by air-cooling only, together with good strength, toughness and fatigue- and wear-resistance.
摘要翻译: 双相贝氏体/马氏体组织的空气硬化钢基本上由C:0.10〜0.7%,Si:0.1〜2%,Mn:2.1〜3.5%,B:0.005〜0.005%,Cr:3.5%以下,优选含有Cr量 至少0.1%,平衡Fe,除了杂质。 可选元素可达1.5%W,1.0%Mo,0.15%V,0.2%S,0.1%Ca,0.1%Pb,0.1%Ti和0.2%总稀土。 至少1.0%的Cr是特别优选的,如果低于该量,则总Mn和Si至少为3%,在这种情况下,如果C在0.47%以下,则存在至少0.6%的Si。 钢可以硬化到Rc 2o到Rc 58,并且通过仅通过空气冷却,并且具有良好的强度,韧性和耐疲劳性和耐磨性,其可固化直径在35mm至80-100mm的范围内。
-
公开(公告)号:US20050058607A1
公开(公告)日:2005-03-17
申请号:US10977088
申请日:2004-10-29
申请人: Donghao Chen , Richard Batycky , LIoyd Johnson , Jeffrey Mintzes
发明人: Donghao Chen , Richard Batycky , LIoyd Johnson , Jeffrey Mintzes
IPC分类号: A61K9/72 , A61K9/00 , A61K9/14 , A61K9/16 , A61K47/24 , A61L9/04 , B05D7/00 , E02F5/10 , F26B3/00
CPC分类号: A61K9/0075 , A61K9/1694 , Y10S514/951
摘要: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
-
公开(公告)号:US4957702A
公开(公告)日:1990-09-18
申请号:US283491
申请日:1988-12-12
申请人: Hongsheng Fang , Yankang Zheng , Xiuyun Chen , Donghao Chen , Rufa Zhao
发明人: Hongsheng Fang , Yankang Zheng , Xiuyun Chen , Donghao Chen , Rufa Zhao
IPC分类号: C22C38/38
CPC分类号: C22C38/38
摘要: Air-hardenable steels of duplex bainite/martensite microstructure consisting essentially of 0.10 to 0.7% C, 0.1 to 2% Si, 2.1 to 3.5% Mn, 0.0005 to 0.005% B, up to 3.5% Cr and preferably containing Cr in amount of at least 0.1%, balance Fe except for incidental impurities. Optional elements are up to 1.5% W, 1.0% Mo, 0.15% V, 0.2% S, 0.1% Ca, 0.1% Pb, 0.1% Ti and 0.2% total rare earths. At least 1.0% Cr is especially preferred and if below such amount, total Mn and Si is at least 3% and in such case, if C is under 0.47%, at least 0.6% Si is present. The steels are hardenable to R.sub.c 20 to R.sub.c 58 and have a hardenable diameter in the range between 35 mm and 80 to 100 mm by air-cooling only, together with good strength, toughness and fatigue- and wear-resistance.
摘要翻译: 双相贝氏体/马氏体组织的空气硬化钢基本上由C:0.10〜0.7%,Si:0.1〜2%,Mn:2.1〜3.5%,B:0.005〜0.005%,Cr:3.5%以下,优选含有Cr量 至少0.1%,平衡Fe,除了杂质。 可选元素可达1.5%W,1.0%Mo,0.15%V,0.2%S,0.1%Ca,0.1%Pb,0.1%Ti和0.2%总稀土。 至少1.0%的Cr是特别优选的,如果低于该量,则总Mn和Si至少为3%,在这种情况下,如果C在0.47%以下,则存在至少0.6%的Si。 该钢可以硬化到Rc 20至Rc 58,并且通过仅通过空气冷却具有在35mm和80至100mm之间的范围内的可硬化直径,以及良好的强度,韧性和疲劳和耐磨性。
-
公开(公告)号:US07469488B2
公开(公告)日:2008-12-30
申请号:US10977088
申请日:2004-10-29
CPC分类号: A61K9/0075 , A61K9/1694 , Y10S514/951
摘要: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
摘要翻译: 通过雾化液体进料并使液体进料与例如空气或氮气的干燥气体接触来产生具有特定空气动力特性的喷雾干燥颗粒。 干燥气体的湿度被控制为例如表示为露点,其已知产生具有特定振实密度或空气动力学直径的颗粒。 体积中值几何直径大于约5微米且振实密度小于约0.4g / cm 3的颗粒是优选的。
-
公开(公告)号:US20080253971A9
公开(公告)日:2008-10-16
申请号:US10420071
申请日:2003-04-18
申请人: David Edwards , Robert Langer , Rita Vanbever , Jeffrey Mintzes , Jue Wang , Donghao Chen
发明人: David Edwards , Robert Langer , Rita Vanbever , Jeffrey Mintzes , Jue Wang , Donghao Chen
CPC分类号: A61K9/0073 , A61K9/0075 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1647 , A61K9/1658 , A61K9/1694 , A61K31/135 , A61K31/137 , A61K31/566 , A61K38/28 , A61K38/38 , A61K47/12 , A61K47/183 , A61K47/24 , A61K47/6927
摘要: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
-
公开(公告)号:US20080226730A1
公开(公告)日:2008-09-18
申请号:US11860302
申请日:2007-09-24
申请人: Jennifer L. Schmitke , Donghao Chen , Richard P. Batycky , David A. Edwards , Jeffrey S. Hrkach
发明人: Jennifer L. Schmitke , Donghao Chen , Richard P. Batycky , David A. Edwards , Jeffrey S. Hrkach
CPC分类号: A61K9/1617 , A61K9/0075 , A61K38/28 , A61K47/544
摘要: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.
摘要翻译: 本发明一般涉及具有包含磷脂,生物活性剂和赋形剂以及其肺部递送的颗粒的制剂。 公开了干粉吸入胰岛素制剂。 公开了包含可用于治疗糖尿病的DPPC,胰岛素和柠檬酸钠的改进制剂。 此外,本发明涉及一种用于肺部递送生物活性剂的方法,包括向需要治疗的患者的呼吸道施用或相关地诊断包含生物活性剂或其任何组合的有效量的颗粒,其中 药剂从施用的颗粒的释放以快速方式发生。
-
公开(公告)号:US07052678B2
公开(公告)日:2006-05-30
申请号:US10094955
申请日:2002-03-07
申请人: Rita Vanbever , Robert S. Langer , David A. Edwards , Jeffrey Mintzes , Jue Wang , Donghao Chen
发明人: Rita Vanbever , Robert S. Langer , David A. Edwards , Jeffrey Mintzes , Jue Wang , Donghao Chen
CPC分类号: A61K9/0075 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1647 , A61K9/1658 , A61K31/135 , A61K31/137 , A61K38/28 , A61K38/38 , A61K47/6921
摘要: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a polycationic complexing agent which is complexed with a therapeutic, prophylactic or diagnostic agent or any combination thereof having a charge capable of complexing with the polycationic complexing agent upon association with the bioactive agent. The particles can further comprise a pharmaceutically acceptable carrier. The amount of polycationic complexing agent present in the particles is an amount sufficient to sustain the release of diagnostic, therapeutic or prophylactic agent from the particles. For example, the amount of complexing agent present can be at about 5% weight/weight (w/w) or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. Release of the agent from the administered particles occurs in a sustained fashion.
-
-
-
-
-
-
-
-
-